<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Veen, R.L.P. van</title>
    <link>http://repub.eur.nl/res/aut/12274/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>In Vivo Optical Measurements for  Diagnostics and Monitoring of Treatment (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/10483/</link>
      <pubDate>2006-06-27T00:00:00Z</pubDate>
      <description>The interaction of light with tissue and its use for medical purposes has been under 
investigation for centuries. Since the early nineteen sixties, the development of novel 
optical technology and advances in laser design/technology allowed a wide range of 
innovative applications in many fields of medicine. For the majority of light applications 
in medicine the distribution of light within tissue is of fundamental importance. The light 
distribution is determined by the optical properties of the tissue; scattering and absorption. 
This thesis focuses on two applications of light in medicine, photodynamic therapy (PDT) 
and optical diagnostics. For each application the effect of differences in and changes of 
tissue optical properties are investigated. The distribution of light within tissue is of vital 
importance in PDT and is strongly dependent on the in vivo optical properties. In vivo 
differences and variations in optical properties are also critically important for optical 
diagnostics. The hypothesis presented is that the underlying cause of the current 
limitations in clinical PDT and low sensitivity in optical diagnosis are due to the 
heterogeneous and dynamic nature of tissue optical properties. This thesis tests this 
hypothesis by investigating the spatial distribution, inter patient differences, and temporal 
behaviour of in vivo optical properties by means of in vivo light measurement.</description>
    </item> <item>
      <title>5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial (Article)</title>
      <link>http://repub.eur.nl/res/pub/8296/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Photochemical and thermal methods are used for ablating
      Barrett's oesophagus (BO). The aim of this study was to compare
      5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with argon
      plasma coagulation (APC) with respect to complete reversal of BO. METHODS:
      Patients with BO (32 no dysplasia and eight low grade dysplasia) were
      randomised to one of three treatments: (a) ALA-PDT as a single dose of 100
      J/cm(2) at four hours (PDT100; n = 13); (b) ALA-PDT as a fractionated dose
      of 20 and 100 J/cm(2) at one and four hours, respectively (PDT20+100; n =
      13); or (c) APC at a power setting of 65 W in two sessions (APC; n = 14).
      If complete elimination of BO was not achieved by the designated
      treatment, the remaining BO was treated by a maximum of two sessions of
      APC. RESULTS: Mean endoscopic reduction of BO at six weeks was 51% (range
      20-100%) in the PDT100 group, 86% (range 0-100%) in the PDT20+100 group,
      and 93% (range 40-100%) in the APC group (PDT100 v PDT20+100, p&lt;0.005;
      PDT100 v APC, p&lt;0.005; and PDT20+100 v APC, NS) with histologically
      complete ablation in 1/13 (8%) patients in the PDT100 group, 4/12 (33%) in
      the PDT20+100 group, and 5/14 (36%) in the APC group (NS). Remaining BO
      was additionally treated with APC in 23/40 (58%) patients. Histological
      examination at 12 months revealed complete ablation in 9/11 (82%) patients
      in the PDT100 group, in 9/10 (90%) patients in the PDT20+100 group, and in
      8/12 (67%) patients in the APC group (NS). At 12 months, no dysplasia was
      detected. Side effects (that is, pain (p&lt;0.01), and nausea and vomiting
      (p&lt;0.05)) and elevated liver transaminases (p&lt;0.01) were more common after
      PDT than APC therapy. One patient died three days after treatment with
      PDT, presumably from cardiac arrhythmia. CONCLUSION: APC alone or ALA-PDT
      in combination with APC can lead to complete reversal of Barrett's
      epithelium in at least two thirds of patients when administered in
      multiple treatment sessions. As the goal of treatment should be complete
      reversal of Barrett's epithelium, we do not recommend these techniques for
      the prophylactic ablation of BO.</description>
    </item>
  </channel>
</rss>